Minimal residual disease (MRD) monitoring in chronic myelogenous leukemia (CML) patients treated with STI571 (Glivec®)

被引：0
|
作者：
Roche-Lestienne, C
Grardel-Duflos, N
Cornu-Soenen, V
Laï, JL
Roumier, C
Berthaud, P
Cosson, A
Facon, T
Preudhomme, C
机构：
来源：
LEUKEMIA | 2001年 / 15卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2023 / 2023
页数：1
相关论文
共 50 条
  • [1] Minimal residual disease (MRD) monitoring by quantitative RT-PCR (RQ PCR) and FISH in chronic myelogenous leukemia (CML) patients treated with STI571 (Gleevec®).
    Roche, C
    Grardel, N
    Cornu-Soenen, V
    Laï, JL
    Roumier, C
    Berthaud, P
    Chatelain, N
    Cosson, A
    Facon, T
    Preudhomme, C
    BLOOD, 2001, 98 (11) : 615A - 615A
  • [2] Pharmacogenetic analysis of cytogenetic response in chronic myelogenous leukemia patients treated with imatinib (Glivec®/Gleevec™, STI571).
    Malinowski, RH
    Dressman, M
    McLean, LA
    Gathmann, I
    Capdeville, R
    BLOOD, 2002, 100 (11) : 547A - 547A
  • [3] The type of the bcr-abl transcript predicts the cytogenetic responses in chronic myelogenous leukemia patients treated with Glivec(STI571).
    Plouzeau, C
    Petinay, P
    Guilhot, J
    Brizard, F
    Bourmeyster, N
    Kitzis, A
    Brizard, A
    Bertaud, P
    Guilhot, F
    BLOOD, 2001, 98 (11) : 266B - 266B
  • [4] Treatment of residual disease in chronic myeloid leukemia with STI-571 (Glivec)
    Geissler, K
    Agis, H
    Sagaster, V
    ACTA MEDICA AUSTRIACA, 2002, 29 : 66 - 68
  • [5] Apoptotic synergism between histone deacetylase (HDAC) inhibitor and imatinib mesylate (STI571, Glivec®) on chronic myelogenous leukemia (CML) cell lines
    Kim, Byung-Su
    Choi, Yong-Hee
    Kim, Young Jue
    Bae, Eun Kyung
    Ahn, Kwang-Sung
    Park, Seonyang
    Kim, Byoung Kook
    Kim, Yeul Hong
    Yoon, Sung-Soo
    ANNALS OF ONCOLOGY, 2004, 15 : 159 - 159
  • [6] Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571
    Chiu, A
    Silver, R
    Rosamillia, M
    Chadburn, A
    MODERN PATHOLOGY, 2001, 14 (01) : 159A - 159A
  • [7] Monitoring minimal residual disease by BCR-ABL Western and quantitative competitive RT PCR in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) on STI571 therapy.
    Quackenbush, RC
    Talpaz, M
    Guo, JQ
    Arlinghaus, RB
    Resta, D
    Capdeville, R
    Rios, MB
    Giles, FJ
    Kantarjian, HM
    BLOOD, 2000, 96 (11) : 736A - 736A
  • [8] Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571
    Chiu, A
    Silver, R
    Rosamillia, M
    Chadburn, A
    LABORATORY INVESTIGATION, 2001, 81 (01) : 159A - 159A
  • [9] Der(9) deletions and response to STI571(Glivec®) treatment in chronic phase CML patients.
    Cuthbert, GD
    Freeman-Edward, JC
    Lennard, AL
    Chase, A
    Capdeville, R
    Goldman, JM
    O'Brien, SG
    Bown, NP
    BLOOD, 2001, 98 (11) : 256B - 256B
  • [10] STI571 (glivec) in the treatment of patients with chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation (allo SCT)
    Pfeifer, H
    Wassmann, B
    Scheuring, U
    Binckebanck, A
    Atta, J
    Brück, P
    Martin, H
    Bartmann, M
    Gschaidmeier, H
    Thiede, C
    Bomhäuser, M
    Hoelzer, D
    Ottmann, OG
    BONE MARROW TRANSPLANTATION, 2002, 29 : S34 - S34
12345